Since 1991, our key priority has been to undertake research to improve patient care and medical practice in the treatment of gastro-intestinal (GI) cancer.
The Australasian Gastro-Intestinal Trials Group (AGITG) incorporated as a Company Limited by Guarantee in 2000 and now encompasses a wide range of medical specialists, scientists, nurses, allied health professionals and consumers. The GI Cancer Institute is the community division of the AGITG, working across Australia to raise funds and awareness of GI cancer and clinical trials.
As a group we have led and designed global studies with a focus on gastro-intestinal cancer. This includes cancer of the oesophagus, stomach, liver, pancreas, gallbladder, large and small bowel, rectum and anus.
The AGITG also plays a major role in clinical trial research, globally, with links in the United Kingdom, Europe, Asia and North America.
As a result, the AGITG has been integral to worldwide changes in medical practice in a number of GI cancers, including gastric, pancreatic, colorectal, oesophageal and biliary tract cancers and gastrointestinal stromal tumour (GIST). The group has led trials in the treatment of stomach and rectal cancer and established surgical guidelines in Australia for pancreatic cancer, among other significant achievements.
In 2008, recognising the need for greater involvement from GI cancer patients, survivors, carers and family members, we established the Consumer Advisory Panel (CAP). Most importantly, the CAP provides advice to the AGITG on general research directions and priorities from a consumer perspective.
We are committed to changing outcomes for people with GI cancer.
To learn more about our research visit Clinical Trials & Research.